Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCAR-AMDR Cells in Relapsed/Refractory Acute Myeloid Leukemia
NCT05654779Phase 1Terminated
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Dec 2022
- Primary completion
- Sep 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LCAR-AMDR in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Treatment-Emergent Adverse Events at 2 years, Recommended Phase 2 Dose at 30 days and 1 more. Started Dec 2022; status: terminated.
02
Drugs
LCAR-AMDR
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05654779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05654779.